The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,Taiwan ,United States ,Hong Kong ,Suzhou ,Jiangsu ,Macau ,Chinese ,Innovent Biologics ,Clin Gastroenterol ,Adimab Incyte ,Yongjun Liu ,Pprofessor Shukui Qin ,Eli Lilly ,National Health Commission ,Cancer Center ,Md Anderson Cancer Center ,Liver Cancer ,National Medical Products Administration ,Innovent Biologics Inc ,Incyte Corporation ,Chinese Society Of Clinical Oncology ,New Drug Application ,Shukui Qin ,Nanjing Jinling Hospital ,Hepatocellular Carcinoma ,Strategic Cooperation ,Mainland China ,Main Board ,Stock Exchange ,Hong Kong Limited ,Lancet Oncology ,Clinical Oncology ,Health Commission ,Primary Liver Cancer ,Opin Biol ,